Ironwood Tries To Hit for The Cyclerion With Spinoff On Deck As Spring Training Winds Down | Value Investing News

Ironwood Tries To Hit for The Cyclerion With Spinoff On Deck As Spring Training Winds Down

  • Born as Microbia over twenty years ago, Ironwood Pharmaceuticals(IRWD) trades just 21% above its 2010 IPO price.
  • It has managed to get to market with LINZESS, a treatment for IBS.
  • Partnered with Allergan(AGN), LINZESS did $761.2 million in 2018 US sales.
Rating: 
No votes yet
Article Link: 
Shared Count: 
1
Value Score: 
1
Category: